These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 29194620)

  • 1. Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases.
    Tavakolpour S; Darvishi M; Ghasemiadl M
    Clin Genet; 2018 Mar; 93(3):481-497. PubMed ID: 29194620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges.
    Tavakolpour S
    Immunol Lett; 2017 Oct; 190():130-138. PubMed ID: 28797806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy.
    Danesi R; Mosca M; Boggi U; Mosca F; Del Tacca M
    Mol Med Today; 2000 Dec; 6(12):475-82. PubMed ID: 11099953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role and impact of SNPs in pharmacogenomics and personalized medicine.
    Laing RE; Hess P; Shen Y; Wang J; Hu SX
    Curr Drug Metab; 2011 Jun; 12(5):460-86. PubMed ID: 21453271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implementation of pharmacogenetics.
    García-González X; Cabaleiro T; Herrero MJ; McLeod H; López-Fernández LA
    Drug Metab Pers Ther; 2016 Mar; 31(1):9-16. PubMed ID: 26751902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
    Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
    Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic markers in methotrexate treatments.
    Giletti A; Esperon P
    Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized therapies in pediatric inflammatory and autoimmune diseases.
    Stocco G; De Iudicibus S; Franca R; Addobbati R; Decorti G
    Curr Pharm Des; 2012; 18(35):5766-75. PubMed ID: 22726111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future prospects for pharmacogenetics in the quest for personalized medicine.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Dec; 50(12):13-6. PubMed ID: 23457712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Pharmacogenomics in Personalized Medicine.
    Singh DB
    Adv Biochem Eng Biotechnol; 2020; 171():369-394. PubMed ID: 31485703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
    Iyer PM; Karthikeyan S; Sanjay Kumar P; Krishnan Namboori PK
    Funct Integr Genomics; 2017 Jul; 17(4):375-385. PubMed ID: 28470340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics in the age of personalized medicine.
    Dickmann LJ; Ware JA
    Drug Discov Today Technol; 2016; 21-22():11-16. PubMed ID: 27978982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine into health national services: barriers and potentialities.
    Rodríguez Vicente AE; Herrero Cervera MJ; Bernal ML; Rojas L; Peiró AM
    Drug Metab Pers Ther; 2018 Dec; 33(4):159-163. PubMed ID: 30391933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
    Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics, precision medicine, and implications for anesthesia care.
    Kaye AD; Mahakian T; Kaye AJ; Pham AA; Hart BM; Gennuso S; Cornett EM; Gabriel RA; Urman RD
    Best Pract Res Clin Anaesthesiol; 2018 Jun; 32(2):61-81. PubMed ID: 30322465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine.
    Daniel LL; Dickson AL; Chung CP
    Clin Rheumatol; 2021 Jan; 40(1):65-73. PubMed ID: 32617765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.